• FDA accepted uniQure's approval application for Huntington's disease gene therapy ifezuntirgene inilparvovec, granting priority review.
• The agency set a May 1, 2027, target decision date under the accelerated approval pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020705OMX_____CNEWS_EN_GNW9857440_en) on November 02, 2026, and is solely responsible for the information contained therein.